Worldwide Healthcare Trust Plc

Worldwide Healthcare Trust Plc

Sector: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices Region: United Kingdom

: | London Stock Exchange: WWH

Worldwide Healthcare Trust Plc is a closed-end investment fund/investment trust. The company invests in pharmaceutical, biotechnology and related companies in the healthcare sector. The company was founded on February 14, 1995 and is headquartered in London, UK.


Martin Smith , Chairman
Martin Smith, aged 68, joined the Board in 2007. He was a founder of Phoenix Securities, a private investment banking firm. Following the acquisition of Phoenix in 1997 by Donaldson Lufkin and Jenrette (DLJ), he chaired DLJ’s European Investment Banking Group. He subsequently founded and was a non executive director of New Star Asset Management Group PLC. He attended Oxford University and has an MBA from Stanford University.
Sarah Bates, Board Member
Member of the Audit Committee and the Nominations and Management Engagement and Remuneration Committees Sarah Bates joined the Board in 2013. She is currently Chairman of JPMorgan American Investment Trust plc, Witan Pacific Investment Trust plc and St James’s Place plc. She is also a non-executive Director of Polar Capital Technology Trust plc. Sarah is a former Chairman of the Association of Investment Companies. She is also a member of the Universities Superannuation Fund Investment Committee and an advisor to the East Riding Pension Fund and has a number of voluntary appointments on charity or pension fund investment committees. She attended Cambridge University and has an MBA from London Business School.
Dr David Holbrook, Board Member
Dr David Holbrook, aged 51, joined the Board in 2007. He is a qualified physician and a Director of MTI Partners Limited, a leading technology venture capital investor. He attended London and Oxford Universities, and has an MBA from Harvard Business School. He has held senior positions in a number of blue chip biopharmaceutical organisations including GlaxoSmithKline and Roche.
Samuel D. Isaly, Board Member
Sam Isaly, aged 66, joined the Board at launch in 1995. Sam is Managing Partner of OrbiMed Capital LLC, the Company’s Investment Manager, and has been an international pharmaceutical investment specialist for more than 20 years having worked in New York and Europe with Chase Manhattan, Société Générale, Crédit Suisse and UBS Warburg.
Humphrey van der Klugt, Board Member
Chairman of the Audit Committee and a member of the Nominations and Management Engagement and Remuneration Committees. Humphrey van der Klugt joined the Board in 2016. He is a Director of JPM Claverhouse Investment Trust plc and Allianz Technology Trust PLC. He was formerly Chairman of Fidelity European Values PLC and a Director of Murray Income Trust PLC and BlackRock Commodities Income Investment Trust plc. Prior to this Humphrey was a fund manager and Director of Schroder Investment Management Limited and in a 22 year career was a member of their Group Investment and Asset Allocation Committees. Prior to joining Schroders, he was with Peat Marwick Mitchell & Co (now KPMG) where he qualified as a Chartered Accountant in 1979.

News & Analysis